Lexaria Bioscience Corp.
LEXX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001348362
No open-market purchases or sales by Lexaria Bioscience Corp. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $920.0K in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Lexaria Bioscience Corp. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Of which not filed for Q1 2022 | Q1 2022 | Change |
|---|---|---|---|---|
| Holders | 13 | 1 | 12 | 0 |
| Shares | 457.5K | 2.69K | 472.6K | +17.9K (+3.9%) |
| Value | $1.85M | $11.0K | $1.41M | −$430.0K (−23.4%) |
1 institution that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (2)
Institutions that held Lexaria Bioscience Corp. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 12,026 | $40.0K | 0.00% |
| 1832 Asset Management L.P. | 2,686 | $9.00K | 0.00% |
Sold out (2)
Institutions that held Lexaria Bioscience Corp. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Edge Wealth Management LLC | 3,333 | $13.0K |
| Morgan Stanley | 1 | $0 |
Not filed for Q1 2022 yet (1)
Institutions that held Lexaria Bioscience Corp. at the end of Q4 2021 and haven't filed a 13F for Q1 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| MD Financial Management Inc. | 2,686 | $11.0K |